Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-1107P denotes a *pseudogene* derived from U6 small nuclear RNA, a crucial non-coding RNA involved in the spliceosome machinery for splicing precursor mRNA in eukaryotes[3][1][5]. Pseudogenes such as RNU6-1107P arise through genomic duplication or retrotransposition events and are widespread across vertebrate genomes, serving as evolutionary records rather than active molecules[4][7][8]. Unlike the canonical U6 snRNA, which is intensely conserved and essential for catalyzing intron removal during mRNA splicing[1][3][5], the pseudogene variant is generally transcriptionally silent and lacks any known biological function, interaction, or disease relevance[7][8]. These pseudogenes may occasionally contribute to genome evolution or serve as molecular markers of retrotransposition dynamics[7], but they do not encode proteins, receptors, or other actionable therapeutic targets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1107, pseudogene (RNU6-1107P).